Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Onconetix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Onconetix's regulatory disclosures and financial reporting.
Onconetix, Inc. appointed David White as Chief Executive Officer effective March 18, 2026 and Sammy Dorf as a director and Audit Committee member effective March 19, 2026.
The company states these leadership changes come as it advances a definitive agreement to acquire Realbotix LLC and intends to file a Registration Statement on Form S-4 to register Onconetix common stock to be issued in the transaction.
Onconetix, Inc. is asking stockholders at an April 30, 2026 special meeting to approve authority for one or more reverse stock splits of its common stock at ratios between 1-for-2 and 1-for-10, with all such splits together capped at 1-for-100 and usable for one year.
The aim is to maintain compliance with Nasdaq’s $1.00 minimum bid requirement after prior notices under the Bid Price Rule and Low Priced Stocks Rule, and to support liquidity and future capital-raising. A second proposal would allow adjournment of the meeting to solicit additional proxies. There were 692,927 common shares outstanding as of March 13, 2026.
Onconetix, Inc. filed an initial insider ownership report for Chief Executive Officer David Allan White on Form 3. This filing establishes his status as an executive officer and subject to insider reporting rules, but it does not disclose any specific stock transactions or option exercises.
Onconetix, Inc. director Sammy Dorf filed an initial ownership report on Form 3. This filing establishes his status as a director and brings his equity position under Section 16 reporting, but it does not list any transactions, purchases, or sales of Onconetix stock.
Onconetix, Inc. has implemented a 1-for-5 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 25, 2026. The company’s shares continue to trade on The Nasdaq Capital Market under the symbol ONCO with a new CUSIP number 68237Q 302.
Every five issued and outstanding shares of common stock were automatically converted into one share, with no change to the par value and no reduction in the number of authorized shares. The reverse split reduced the number of issued and outstanding shares from 3,464,686 to 692,927 and is intended to help the company maintain compliance with Nasdaq’s $1.00 minimum bid price requirement.
No fractional shares were issued; instead, stockholders entitled to a fractional share receive cash based on the closing sale price on March 24, 2026, adjusted for the split. Proportional adjustments were also made to equity awards, convertible preferred stock, and warrants.
Onconetix highlights Realbotix participation in Ericsson’s live pre-standard 6G over-the-air trial and reiterates its pending acquisition of Realbotix LLC. A Realbotix humanoid robot served as a live connected endpoint transmitting video and interacting in real time over Ericsson’s test network. Onconetix entered a definitive share exchange agreement to acquire 100% of Realbotix LLC in an all-stock transaction; closing is anticipated in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.
Onconetix, Inc. filed an amended report to add the employment agreement for its new Chief Executive Officer, David White, as an exhibit. The amendment does not change any prior disclosures.
The Board appointed Mr. White as CEO effective March 18, 2026, under an employment agreement providing a monthly base salary of $21,700 and customary non-compete, confidentiality and non-solicitation covenants. In connection with his appointment, monthly compensation was reduced by $5,000 for interim CFO Karina Fedasz and by $26,000 for Lead Independent Director Andrew Oakley.
Separately, director Timothy Ramdeen resigned from the Board and its key committees on March 19, 2026, with the company stating his departure was not due to any disagreement over operations or policies. The Board appointed Sammy Dorf as a new director and member of the Audit Committee, adding capital-markets and governance experience.
Onconetix, Inc. appointed David White as Chief Executive Officer effective March 18, 2026, formalizing leadership after an interim period. White brings more than 30 years of executive and board experience across transportation, healthcare, and manufacturing, including prior CEO, CFO, and COO roles and multiple public company directorships.
Under his employment agreement, White will receive a monthly base salary of $21,700 and is subject to non-compete, confidentiality, and non-solicitation covenants. In connection with his appointment, monthly compensation was reduced by $5,000 for Interim CFO Karina Fedasz and by $26,000 for Lead Independent Director Andrew Oakley, effective March 18, 2026.
Separately, director Timothy Ramdeen resigned from the Board and its key committees on March 19, 2026, with the company stating his departure was not due to any disagreement with management or the Board. The Board appointed entrepreneur and investor Sammy Dorf as a new director and Audit Committee member, adding capital markets and governance experience. Both White and Dorf are described as independent, with no family relationships or related-party transactions requiring disclosure.
Onconetix, Inc. is seeking stockholder approval at a Special Meeting on April 30, 2026 to authorize the Board to implement one or more reverse stock splits at ratios between 1-for-2 and 1-for-10 (aggregate up to 1-for-100) and to approve an adjournment power.
The Board unanimously recommends a FOR vote. The Record Date for voting is March 13, 2026, and 3,473,352 shares of Common Stock were outstanding as of that date. The proposal would let the Board decide timing and the final ratio, and any Reverse Stock Split would become effective upon filing an amendment with Delaware.
Onconetix, Inc. filed its annual report describing a pivot to men’s health diagnostics centered on Proclarix, a blood test for clinically significant prostate cancer, while warning of serious liquidity pressure. Proclarix generated only $23,091 of revenue in 2025, so the business remains early-stage and loss‑making.
As of December 31, 2025, Onconetix reported cash of $5.2 million, a working capital deficit of about $3.1 million, an accumulated deficit of roughly $131.2 million, and operating cash use of about $9.7 million in 2025; cash was $3.6 million as of March 11, 2026. Management concludes these factors raise substantial doubt about the company’s ability to continue as a going concern.
The company abandoned commercialization of ENTADFI, fully impaired those assets, settled about $8.8 million of related Veru notes through a mix of cash and securities, and now relies on external financing. A Share Exchange Agreement with Realbotix could transfer 75–90% of fully diluted equity to the seller, depending on Net Cash at closing, and requires at least $12.5 million of Net Cash plus a committed $125.0 million equity line. Onconetix previously regained Nasdaq compliance through a 1‑for‑85 reverse stock split and is under panel monitoring until July 7, 2026.